A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice
- 18 October 2017
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 26 (4) , 365-372
Abstract
E75 (HER-2/neu-369–377), is an immunogenic peptide which is highly expressed in breast cancer patients. The purpose of this study was to develop an effective vaccine delivery/adjuvant system by attachment of this peptide to the surface of liposomes consisting of phospholipids including distearoylphosphocholine (DSPC) and distearoyl phosphoglycerol (DSPG) with high transition temperature (Tm) and dioleoylphosphatidylethanolamine (DOPE) (a pH-sensitive lipid for cytosolic antigen delivery) to improve antitumour immune activity against the E75 peptide. For this purpose, the E75 peptide was incorporated into liposomes consisting of DSPC/DSPG/cholesterol (Chol)/DOPE (15/2/3/5 molar ratio) through conjugation with distearoylphosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (maleimide-PEG2000-DSPE). Immunization of BALB/c mice was performed three times with different forms of liposomal formulations at 2-week intervals and antitumour immunity responses were evaluated. Results of ELISpot and flow cytometry analysis showed that mice vaccinated with DSPC/DSPG/Chol/DOPE/E75 have significantly enhanced the antigen-specific IFN-γ response of CD8+ T cells and generated cytotoxic T lymphocytes (CTL) antitumour responses. CTL responses induced by this formulation resulted in inhibition of tumour progression and longer survival time in the mice TUBO tumour model. The results revealed that the liposomes consist of DSPC/DSPG/Chol/DOPE could be suitable candidates for vaccine delivery of E75 peptide for the prevention and therapy of HER2-positive breast cancer and merit further investigation.Keywords
Funding Information
- Mashhad University of Medical Sciences
This publication has 45 references indexed in Scilit:
- Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensVaccine, 2012
- Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patientsCancer, 2011
- Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccineCancer, 2010
- Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical TrialJournal of the American College of Surgeons, 2010
- The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2009
- Induction of Cytotoxic T-Lymphocytes and Antitumor Activity by a Liposomal Lipopeptide VaccineMolecular Pharmaceutics, 2008
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- INFLUENCE OF PHOSPHOLIPID COMPOSITION ON THE ADJUVANTICITY AND PROTECTIVE EFFICACY OF LIPOSOME-ENCAPSULATED LEISHMANIA DONOVANI ANTIGENSJournal of Parasitology, 2005
- Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8Human Immunology, 1997
- Immunological adjuvants: a role for liposomesImmunology Today, 1990